Evidence map›Paper›PMID 42715308›Full record

ArticleScience advances2026

Spatiotemporal mapping of tertiary lymphoid structure heterogeneity shapes immune niches and clinical outcomes in intrahepatic cholangiocarcinoma.

Liaoliao Gao, Jie Mei, Libing Hong, Yuzhi Jin, Jinlin Cheng, Xuqi Sun, Chuan Liu, Bin Li, Xiaomeng Dai, Bo Lin and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Liaoliao GaoDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID 0009-0003-4227-5889
Jie MeiDepartment of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.ORCID 0000-0002-5676-4216
Libing HongDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID 0009-0007-6049-7206
Yuzhi JinDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID 0009-0001-7462-8058
Jinlin ChengState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xuqi SunDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID 0000-0002-3975-9917
Chuan LiuDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Bin LiDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID 0000-0002-5324-3554
Xiaomeng DaiDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID 0000-0003-0673-1886
Bo LinSchool of Software, Zhejiang University, Ningbo, China.ORCID 0000-0001-5682-2140
Yajie SunCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.ORCID 0000-0003-4611-230X
Peng ZhaoDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID 0000-0002-5479-899X
Minshan ChenDepartment of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Rongping GuoDepartment of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Shan XinDepartment of Genetics, Yale School of Medicine, New Haven, USA.ORCID 0000-0002-4735-0935
Jingping YunState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.ORCID 0000-0002-1001-0769
Inmaculada Martínez-ReyesGerman Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0003-0479-1535
Wei WeiDepartment of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.ORCID 0000-0003-0059-8447
Weijia FangDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID 0000-0001-9849-347X
Xuanwen BaoDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID 0000-0002-6232-3783

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal malignancy with limited therapeutic options. The spatial architecture and functional diversity of tertiary lymphoid structures (TLSs) in iCCA remain unclear. Here, we present a multimodal spatial atlas of TLSs and identified intratumoral TLSs (iTLSs) as independent prognostic markers. Bulk proteomic profiling of 214 discovery and 155 validation cases identified a four-tier TLS-based tumor microenvironment classification system and supported development of a TLS-predictive random forest classifier. Imaging mass cytometry revealed that iTLS

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaTertiary Lymphoid StructuresTumor MicroenvironmentChemokine CXCL12Dendritic CellsHumansMacrophagesPrognosisProteomicsSpatial TranscriptomicsChemokine CXCL12

Identifiers

PMID42715308
PMCPMC13557079

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.